Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINELAND: First-Line Lenvatinib in Child-Pugh B HCC Patients Unsuitable for Curative Treatment
KCT0011269Phase 2Recruiting
- Sponsor
- Boryung
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Boryung. Started Apr 2026; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0011269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011269.